Navigation Links
Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic
Date:1/28/2008

Proceeds to Fund U.S. Clinical Trials of Trilobal Tissue Heart Valve and

Implantation Technologies

IRVINE, Calif., Jan. 28 /PRNewswire/ -- Arbor Surgical Technologies, Inc., a privately held medical device company, announced today the closing of a $20 million dollar Series C financing round. Medtronic Inc. led the investment as part of a licensing agreement that was reached between the two companies. The agreement provides Medtronic with manufacturing, marketing and distribution rights to Arbor's advanced trilobal pericardial valve technologies. Financial terms of the license agreement have not been disclosed. Arbor retains exclusive rights to the modular Trilogy(TM) Aortic Valve System and sutureless TRE(TM) implantation technologies. "I am truly excited about this opportunity." said Dr. John Liddicoat, Vice President and General Manager of Medtronic Structural Heart Disease. "No other comparable technology is on the horizon." Existing Arbor investors also participated in this new round of financing. With the closing of this event, Arbor has raised approximately $54 million dollars to date.

"We are excited to complete this milestone round of financing. Recognition from such a major player in the industry confirms the value of our technology," said Steve Bacich, President and Chief Executive Officer of Arbor. "This financing event will allow us to expand clinical trials of our core technologies, the Trilogy(TM) Aortic Valve System and the sutureless TRE(TM) implantation tool. These devices are designed to enable more surgeons to perform minimally invasive heart valve procedures. We believe that the adoption of Arbor's products will improve the lives of heart valve patients worldwide."

About Arbor Surgical Technologies, Inc.

Arbor Surgical Technologies, Inc., (http://www.arborsurgical.com) with facilities in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular device company focused on the minimally invasive heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted valve designer, Ernie Lane, Arbor is developing technologies intended to deliver significant clinical benefits to patients worldwide. The Trilogy(TM) Aortic Valve System and TRE(TM) attachment technologies are designed to expand the use of minimally invasive heart valve procedures.

Contact:

Steve Bacich

President and CEO of Arbor Surgical Technologies, Inc.

949-598-8800

sbacich@arborsurgical.com


'/>"/>
SOURCE Arbor Surgical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
2. Ann Arbor SPARK Receives $3.75M from Michigans Company Formation & Growth Fund
3. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
4. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
5. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
6. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
7. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
8. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
9. Neptune Technologies receives GRAS notification in the United States
10. VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7
11. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) with ... (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president of ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):